Waverley Pharma Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Larry Thiessen

Algemeen directeur

CA$45.0k

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	4.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	4.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Larry Thiessen's beloning veranderd ten opzichte van Waverley Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CA$2m
Mar 31 2024	n/a	n/a	-CA$2m
Dec 31 2023	CA$45k	CA$45k	-CA$2m
Sep 30 2023	n/a	n/a	-CA$1m
Jun 30 2023	n/a	n/a	-CA$910k
Mar 31 2023	n/a	n/a	-CA$693k
Dec 31 2022	CA$45k	CA$45k	-CA$664k
Sep 30 2022	n/a	n/a	-CA$725k
Jun 30 2022	n/a	n/a	-CA$810k
Mar 31 2022	n/a	n/a	-CA$934k
Dec 31 2021	CA$45k	CA$45k	-CA$797k
Sep 30 2021	n/a	n/a	-CA$851k
Jun 30 2021	n/a	n/a	-CA$642k
Mar 31 2021	n/a	n/a	-CA$697k
Dec 31 2020	CA$33k	CA$33k	-CA$706k

Compensatie versus markt: De totale vergoeding ($USD 32.38K ) Larry } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 172.63K ).

Compensatie versus inkomsten: De vergoeding van Larry is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Larry Thiessen

4.8yrs

Tenure

CA$45,000

Compensatie

Mr. Larry Thiessen MBA, serves as President and Chief Executive Officer at Waverley Pharma Inc. since February 1, 2020 and also serves as its Director since November 22, 2023. He has extensive pharmaceutic...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Larry Thiessen	President	less than a year	CA$45.00k	geen gegevens
Albert Friesen	Chairman of the Board	7.9yrs	geen gegevens	74.61% CA$ 604.4k
P. Enns	Independent Director	7.9yrs	geen gegevens	0.19% CA$ 1.5k
James Kinley	Director	less than a year	geen gegevens	0.10% CA$ 847.5

4.5yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van WAVE wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).

Waverley Pharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Waverley Pharma Inc. Elects James Kinley as Director

Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Waverley Pharma Inc. Announces Changes to Board of Directors

Recent updates

Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million.

First half 2024 earnings released: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)

Waverley Pharma Inc. Elects James Kinley as Director

First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.041 loss per share (vs CA$0.012 loss in FY 2022)

Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Waverley Pharma Inc. Announces Changes to Board of Directors

Waverley Pharma Inc. Announces Changes to Board of Directors

Insufficient new directors

Insufficient new directors

Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0 in 2Q 2022)

Insufficient new directors

Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023

First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 1Q 2022)

Insufficient new directors

Full year 2022 earnings released: CA$0.012 loss per share (vs CA$0.015 loss in FY 2021)

Insufficient new directors

Waverley Pharma Inc. Provides Update on its PARP-1 Inhibitor Program

Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 3Q 2021)

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: EPS: CA$0 (vs CA$0.003 loss in 2Q 2021)

Insufficient new directors

Insufficient new directors

First quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 1Q 2021)

Full year 2021 earnings released: CA$0.015 loss per share (vs CA$0.013 loss in FY 2020)

Insufficient new directors

Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022

Second quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.004 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.013 loss per share (vs CA$0.022 loss in FY 2019)

Waverley Pharma Announces Tentative ANDA Approval for Pemetrexed in the United States

First half earnings released

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd